A lower dose of docetaxel at 60 mg/m(2) could be continued longer for controlling peripheral edema in patients with metastatic breast cancer

Docetaxel is a key drug for metastatic breast cancer (MBC). In patients with MBC, the treatment objective is durable response with minimum toxicity. In Japan, the approved dose of docetaxel is 60-70 mg/m(2) every 3 weeks, whereas 75-100 mg/m(2) docetaxel is common in the West. We retrospectively exa...

Ausführliche Beschreibung